Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant abemaciclib window-of-opportunity study in low-ER positive, HER2-negative early breast cancer
2020-005792-12Phase 2Completed
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abemaciclib in breast cancer and estrogen receptor-positive breast cancer, sponsored by Gruppo Oncologico Italiano di Ricerca Clinica. Primary endpoint: Change in Ki67. Started Oct 2021; status: completed.
02
Drugs
abemaciclib
03
Conditions
breast cancerestrogen receptor-positive breast cancer
Beyond the preview
Go deeper on 2020-005792-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005792-12.